<SEC-DOCUMENT>0001973379-25-000282.txt : 20251104
<SEC-HEADER>0001973379-25-000282.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104160023
ACCESSION NUMBER:		0001973379-25-000282
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		251448771

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		PROVINCE COUNTRY:   	P7
		ZIP:			1105 BP
		BUSINESS PHONE:		1-339-970-7000

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		PROVINCE COUNTRY:   	P7
		ZIP:			1105 BP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kaye Jack
		CENTRAL INDEX KEY:			0001376099
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O KERYX BIOPHARMACEUTICALS
		STREET 2:		750 LEXINGTON AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001376099</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001590560</issuerCik>
      <issuerName>uniQure N.V.</issuerName>
      <secFileNumber>001-36294</secFileNumber>
      <issuerAddress>
        <com:street1>PAASHEUVELWEG 25A</com:street1>
        <com:city>AMSTERDAM</com:city>
        <com:stateOrCountry>P7</com:stateOrCountry>
        <com:zipCode>1105 BP</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>1-339-970-7000</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Kaye Jack</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>CITIGROUP GLOBAL MARKETS</name>
        <address>
          <com:street1>390 GREENWICH STREET</com:street1>
          <com:city>NEW YORK</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10013</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>38810</noOfUnitsSold>
      <aggregateMarketValue>1330794.00</aggregateMarketValue>
      <noOfUnitsOutstanding>61600000</noOfUnitsOutstanding>
      <approxSaleDate>11/04/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>ORDINARY SHARES</securitiesClassTitle>
      <acquiredDate>11/04/2025</acquiredDate>
      <natureOfAcquisitionTransaction>STOCK OPTION EXERCISE AND SALE PURSUANT TO 10B51 PLAN</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>UNIQURE NV</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>38810</amountOfSecuritiesAcquired>
      <paymentDate>11/04/2025</paymentDate>
      <natureOfPayment>CASH</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>SECTION 3 D BASED ON CLOSING PRICE ON NOV 3 OF 34.29 SECTION 3 E SHARES OR OTHER UNITS OUTSTANDING BASED ON NOV 3 DETAILS
STOCK OPTIONS WERE EXERCISED AND SOLD PURSUANT TO HIS 10B51 PLAN FROM JUNE 2025</remarks>
    <noticeSignature>
      <noticeDate>11/04/2025</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>06/16/2025</planAdoptionDate>
      </planAdoptionDates>
      <signature>CONFORMED SIGNATURE ON FILE</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
